Exploring Gas Transfer and the Utility of Dynamic Chest Radiography in Long Covid Patients

COVID-19 Clinical Trial

— LoCTDC  

Official title:

Exploring Gas Transfer and the Utility of Dynamic Chest Radiography in Long Covid Patients.

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05862896
• Other study ID #: LHS0056
• Status: Not yet recruiting
• Start date: August 1, 2023
• Est. completion date: August 1, 2024

Study information

• Verified date: May 2023
• Source: Liverpool University Hospitals NHS Foundation Trust
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study aims to identify if breathless patients with Long COVID have reduced transfer factor on pulmonary function testing and if the degree of transfer factor reduction is correlated with the symptom severity and physiological ability to exercise. We will also investigate whether a new type of X-ray called a dynamic chest X-ray can identify perfusion abnormalities and whether these correlate with differences in diffusion capacity measured on a pulmonary function test.

Description:

Long COVID is the term used to describe patients who present with persistent symptoms after recovering from SARS-CoV-2 infection. Patients exhibit a range of symptoms and commonly report respiratory and cardiac phenomena including breathlessness, feeling tight chested and having persistent tachycardias. Survey data suggests up to 87% of patients discharged from hospital after COVID-19 infection have ongoing symptoms 60 days after discharge, with 43% describing breathlessness. In the USA, 35% of patients treated for SARS-CoV-2 as an outpatient have ongoing symptoms, with a similar percentage of the population unable to return to their normal work. The natural history and pathophysiology of long COVID is not yet fully understood. Few studies have explored pulmonary function in post-COVID patients. There are suggestions that functional limitation is related to lung abnormalities affecting both ventilation (air flow) and perfusion (blood flow), possibly caused by micro-blood clots. Establishing a relatively cost-effective and accessible way of diagnosing these will allow clinicians to treat or signpost the patients to the correct services. This is vital at both the patient and health system level.

Full pulmonary function testing is routinely done in respiratory clinics to investigate breathlessness and diagnose conditions such as asthma, chronic obstructive pulmonary disease (COPD) and pulmonary fibrosis. It includes a measure of transfer factor, an estimate of the efficiency of the diffusion of gas from the lung into the blood stream. The lungs' ability to absorb carbon monoxide (CO) is measured as a proxy for the ability to absorb oxygen. It is hypothesised that long COVID patients with breathlessness have abnormal gas transfer due to lung tissue damage at an alveolar level and/or perfusion abnormalities such as micro clots. Dynamic X-ray is a new, innovative technology to image the thoracic cavity throughout the breathing cycle allowing assessment of pulmonary function and possibly diagnose small ventilation-perfusion abnormities. Liverpool hosts the only dynamic X-ray machine in Europe. Potential applications beyond COVID are numerous, including filling diagnostic gaps in many lung diseases where expensive lung function testing is an unrealistic possibility in the medium term.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 194
• Est. completion date: August 1, 2024
• Est. primary completion date: August 1, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Adults (over 18 years old)

2. Patients with breathlessness (defined as self-reported modified Borg Scale score of 2 or more when walking on flat ground for 100 metres) that has continued or developed and persists more than 4 weeks after acute COVID 19 i.e., related to 'long COVID' (covid confirmed by photographic evidence of positive lateral flow/NHS application, EMIS records or hospital lab data).

3. Able to achieve positioning for a PA chest X-ray for a 20 second period

4. Able to hold their breath for at least 7 seconds

5. Fluent spoken English - to ensure a comprehensive understanding of the research project and their proposed involvement

6. Able to provide written informed consent

7. For control group: Age, sex matched to participants identified in the affected group

Exclusion Criteria:

1. Any contraindication to pulmonary function testing or DCR

2. Pregnancy

3. For women of childbearing age, a positive pregnancy test or refusal of pregnancy test (a negative urinary pregnancy test on the day of DCR is a requirement)

4. Significant other respiratory co-morbidities as judged by study clinician

5. Significant research related radiation exposure in last 12 months prior to consent (from participation in a previous studies involving radiation exposure, with a research dose constraint of 0.4 mSv)

6. Unable to provide informed consent for any reason

7. For the long covid arm no evidence of a positive covid-19 test

Related Conditions & MeSH terms

• COVID-19

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Liverpool University Hospitals NHS Foundation Trust

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Primary objective	1) To establish the proportion of patients with long COVID that have abnormal transfer factor on pulmonary function testing.	12 months